← Back to all signals
RESEARCH PAPER ANALYSIS

The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A systematic review of human observational studies - Part II: Less researched outcomes.

AI interpretation is pending for this paper.

Open original publication →
PMID39904670
JournalEnvironment international
Publication Date2025-01-11
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: In the framework of the World Health Organization assessment of health effects of exposure to radiofrequency electromagnetic fields (RF-EMF), we have conducted a systematic review of human observational studies on the association between exposure to RF-EMF and risk of neoplastic diseases. Due to the extremely large number of included exposure types/settings and neoplasm combinations, we decided to present the review findings in two separate papers. In the first one we addressed the most investigated exposure-outcome pairs (e.g. glioma, meningioma, acoustic neuroma in relation to mobile phone use, or risk childhood leukemia in relation to environmental exposure from fixed-site transmitters) (Karipidis et al., 2024). Here, we report on less researched neoplasms, which include lymphohematopoietic system tumours, thyroid cancer and oral cavity/pharynx cancer, in relation to wireless phone use, or occupational RF exposure. METHODS: Eligibility criteria: We included cohort and case-control studies of neoplasia risks in relation to three types of exposure to RF-EMF: 1. exposure from wireless phone use; 2. environmental exposure from fixed-site transmitters; 3. occupational exposures. In the current paper, we focus on less researched neoplasms including leukaemia, non-Hodgkin's lymphoma and thyroid cancer in mobile phone users; lymphohematopoietic system tumours and oral cavity/pharynx cancer in exposed workers. We focussed on investigations of specific neoplasms in relation to specific exposure sources (termed exposure-outcome pair, abbreviated E-O pairs), noting that a single article may address multiple E-O pairs. INFORMATION SOURCES: Eligible studies were identified by predefined literature searches through Medline, Embase, and EMF-Portal. Risk-of-bias (RoB) assessment: We used a tailored version of the Office of Health Assessment and Translation (OHAT) RoB tool to evaluate each study's internal validity. Then, the studies were classified into three tiers according to their overall potential for bias (low, moderate and high) in selected, predefined and relevant bias domains. DATA SYNTHESIS: We synthesized the study results using random effects restricted maximum likelihood (REML) models. Evidence assessment: Confidence in evidence was assessed according to the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. RESULTS: We included 26 articles, which were published between 1988 and 2019, with participants from 10 countries, reporting on 143 different E-O pairs, including 65 different types of neoplasms. Of these, 19 E-O pairs satisfied the criteria for inclusion in quantitative syntheses of the evidence regarding the risks of leukaemia, non-Hodgkin's lymphoma or thyroid cancer in relation to mobile phone use, and the risks of lymphohematopoietic system tumours or oral cavity/pharynx cancer following occupational exposure to RF-EMF. RF-EMF exposure from mobile phones (ever or regular use vs no or non-regular use) was not associated with an increased risk of leukaemia [meta-estimate of the relative risk (mRR) = 0.99, 95 % CI 0.91-1.07, 4 studies), non-Hodgkin's lymphoma (mRR = 0.99, 95 % CI = 0.92-1.06, 5 studies), or thyroid cancer (mRR = 1.05, 95 % CI = 0.88-1.26, 3 studies). Long-term (10 + years) mobile phone use was also not associated with risk of leukaemia (mRR = 1.03, 95 % CI 0.85-1.24, 3 studies), non-Hodgkin lymphoma (mRR = 0.99, 95 % CI 0.86-1.15, 3 studies), or thyroid cancer (no pooled estimate given the small number of studies). There were not sufficient studies of any specific neoplasms to perform dose-response meta-analyses for either cumulative call time or cumulative number of calls; individual studies did not show statistically significant associations between lifetime intensity of mobile phone use and any specific neoplasm. Occupational RF-EMF exposure (exposed vs unexposed) was not associated with an increased risk of lymphohematopoietic system tumours (mRR = 1.03, 95 % CI = 0.87-1.28, 4 studies) or oral cavity/pharynx cancer (mRR = 0.68, 95 % CI 0.42-1.11, 3 studies). There were not sufficient studies of any specific neoplasms to perform meta-analysis on the intensity or duration of occupational RF-EMF exposure; individual studies did not show statistically significant associations with either of those exposure metrics and any specific neoplasms. The small number of studies, and of exposed cases in some instances, hampered the assessment of the statistical heterogeneity in findings across studies in the meta-analyses. Based on the summary risk of bias, most studies included in the quantitative evidence syntheses were classified at moderate risk of bias. The most critical issue was exposure information bias, especially for occupational studies where the exposure characterization was rated at high risk of bias for all included studies. Outcome information bias was an issue in mortality-based occupational cohort studies investigating non-rapidly fatal neoplasms. Further, the healthy subscriber effect, and (at a lesser extent) the healthy worker effect, were identified as plausible explanations of the decreased risks observed in some studies. The association of RF-EMF exposure from wireless phone use, or workplace equipment/devices, with other important neoplasms was reported by only one or two studies per tumour, so no quantitative evidence syntheses were conducted on these outcomes. It is noted that there were generally no statistically significant exposure-outcome associations for any combinations, independently of the exposure metric and level, with a few studies reporting decreased risks (especially for smoking-related cancers). There was only one study which assessed the effect of RF-EMF exposure from fixed-site transmitters on less researched neoplasms and it reported no statistically significant associations between exposure from base stations and risk of lymphomas overall, lymphoma subtypes, or chronic lymphatic leukaemia in adults. CONCLUSIONS: For near field RF-EMF exposure to the head from mobile phones, there was low certainty of evidence that it does not increase the risk of leukaemia, non-Hodgkin's lymphoma or thyroid cancer. For occupational RF-EMF exposure, there was very low certainty of evidence that it does not increase the risk of lymphohematopoietic system tumours or oral cavity/pharynx cancer. There was not sufficient evidence to assess the effect of whole-body far-field RF-EMF exposure from fixed-site transmitters (broadcasting antennas or base stations), or the effect of RF-EMF from any source on any other important neoplasms. OTHER: This project was commissioned and partially funded by the World Health Organization (WHO). Co-financing was provided by the New Zealand Ministry of Health; the Istituto Superiore di Sanità in its capacity as a WHO Collaborating Centre for Radiation and Health; and ARPANSA as a WHO Collaborating Centre for Radiation Protection. REGISTRATION: PROSPERO CRD42021236798. Published protocol: [(Lagorio et al., 2021) DOI https://doi.org/10.1016/j.envint.2021.106828].

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The Journey with paediatric cancer: reflections on its impact on patients and their families. The Pan African medical journal 56.0 2 Pars plana vitrectomy in uveitis of diverse etiologies: indications and surgical outcomes. BMC ophthalmology 63.5 3 Persistent Oropharyngeal Hemangioma Causing Progressive Upper Airway Compromise: Diagnostic and Therapeutic Challenges. Cureus 61.64 4 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma. ESMO open 71.84 5 Life Saving Hepatic Resections in Ruptured Pediatric Hepatoblastoma - a Report of 3 Cases. Indian journal of surgical oncology 63.6 6 Development and Internal Validation of the SPR-HCC Score System: A Prognostic Tool for Survival Prediction in Hepatocellular Carcinoma in a Resource-Limited Setting. Asian Pacific journal of cancer prevention : APJCP 72.02 7 Retinoblastoma Incidence in Saudi Arabia: A 20-Year Analysis. Asian Pacific journal of cancer prevention : APJCP 57.5 8 Systemic Immune Inflammation Index as High-Risk Retinoblastoma Survival Predictor. Asian Pacific journal of cancer prevention : APJCP 63.12 9 Predictors of Cervical Cancer Screening Uptake Among Women of Reproductive Age in Indonesia: A Nationwide Cross-Sectional Study Based on the 2023 Indonesian Health Survey. Asian Pacific journal of cancer prevention : APJCP 67.5 10 Effects of estetrol/drospirenone vs drospirenone-only on thrombin generation in women with polycystic ovary syndrome: a randomized, double-blind, controlled trial. Research and practice in thrombosis and haemostasis 77.6 11 Quality indicators for the care of children with CNS tumors: An international modified Delphi study. Neuro-oncology advances 72.0 12 Feasibility, uptake, and exploratory outcomes of an individualized exercise program in pediatric oncology: a prospective single-center pilot study. Frontiers in pediatrics 64.1 13 Prenatal diagnosis and outcomes of fetal cardiac tumors: a 10-year single-center study of 81 cases. Frontiers in medicine 66.0 14 Advances in the association between tumor immune microenvironment remodeling in osteosarcoma and the risk of pathological fractures. Frontiers in genetics 54.3 15 Proximal Phalanx Enchondroma in a Pediatric Patient: Curettage, Liquid Nitrogen Cryotherapy, Iliac Crest Autograft, and Microfragment Plate Fixation. Cureus 61.64 16 Beyond size: the role of growth rate in managing adolescent breast masses. American journal of surgery 68.5 17 Primary ovarian non-small cell neuroendocrine carcinoma in an adolescent: The youngest case reported to date. Pathology, research and practice 45.5 18 Indocyanine Green (ICG) fluorescence-Guided Surgery (FGS) in pediatric Wilms tumor: Opportunities and Challenges. Surgical oncology 47.5 19 Targeting SUV4-20H2-mediated H4K20 methylation restrains growth and migration in pediatric high-grade astrocytomas. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 62.2 20 Timing of breast cancer diagnosis postpartum and survival in women with germline pathogenic variants. ESMO open 71.02 21 Myxoid Pleomorphic Liposarcoma: A Clinicopathological and Cytogenomic Study of 24 Cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 60.7 22 Astragaloside IV is associated with TFRC-dependent ferroptosis and JAK2/STAT3 pathway inhibition in osteosarcoma cells. Biochimica et biophysica acta. General subjects 68.5 23 Purely osteolytic bone lesions in the early osteoarticular phase of synovitis, acne, pustulosis, hyperostosis and osteitis syndrome. BMJ case reports 54.0 24 Spatial Lineage Divergence at Diagnosis in a Pediatric KMT2A-Rearranged Leukemia Presenting with Concurrent AML and B-LBL. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 53.9 25 Temporary Perineal Urethrostomy for Bladder Tumor Resection. Case reports in urology 45.5 26 Public support for policies to create a healthier food environment in Aotearoa New Zealand: findings from a national survey. The New Zealand medical journal 65.2 27 The public in Aotearoa New Zealand support policies to reduce alcohol harm: results from a national survey. The New Zealand medical journal 66.5 28 Public support for government-led skin cancer prevention in Aotearoa New Zealand: findings from a national survey. The New Zealand medical journal 66.6 29 Public support for better controls on lobbying and industry influence in Aotearoa New Zealand: findings from a national survey. The New Zealand medical journal 43.2 30 Aotearoa New Zealanders' views of policies and funding for human papillomavirus vaccination and screening for cervical and lung cancers: a national survey. The New Zealand medical journal 66.4 31 Aotearoa New Zealand public strongly support investment in cancer treatment and care services: findings from a national survey. The New Zealand medical journal 66.94 32 Public support for cancer prevention and care policies in Aotearoa New Zealand: methods of a national survey. The New Zealand medical journal 66.9
PATIENT-FRIENDLY SUMMARY

The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A systematic review of human observational studies - Part II: Less researched outcomes.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic